Missouri Senate Bill SB1682

Missouri 2026 Regular Session

• Introduced: 2/19/26
• Introduced: 12/31/69
• Refer: 4/16/26

Caption

SB 1682

Impact

The bill impacts state laws by providing legal protections for both those administering psilocybin and those using it for treatment. Individuals who are a part of this program will not face civil fines or penalties under state law, provided they adhere to the regulations set forth in the bill. Additionally, the Department of Mental Health is tasked with conducting studies and reporting on the efficacy of psilocybin, which may pave the way for more extensive research and potential changes to how alternative therapies are treated legally in the future.

Summary

Senate Bill 1682 aims to modify current provisions relating to alternative therapies and treatments, specifically focusing on the therapeutic use of psilocybin. This bill allows veterans and first responders who suffer from conditions like post-traumatic stress disorder (PTSD), major depressive disorder, or substance use disorders to legally acquire and use psilocybin for therapeutic purposes. It establishes a framework in which eligible individuals can engage in regulated therapeutic practices involving psilocybin under appropriate supervision.

Contention

Notable points of contention around SB1682 include discussions on the regulation and monitoring of psilocybin use, particularly regarding the potential risks associated with its use. Opponents may raise concerns regarding the safety and effectiveness of psilocybin as a treatment, given its classification and the stigma associated with psychedelic substances. Additionally, ensuring that adequate training requirements for facilitators are met may be a concern, emphasizing the need for a balance between accessibility of treatment and safeguarding public health.